Lexicon Pharmaceuticals 将来の成長
Future 基準チェック /16
Lexicon Pharmaceuticals利益と収益がそれぞれ年間4.7%と18%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に-52.6% 21.7%なると予測されています。
主要情報
4.7%
収益成長率
21.75%
EPS成長率
| Pharmaceuticals 収益成長 | 14.4% |
| 収益成長率 | 18.0% |
| 将来の株主資本利益率 | -52.64% |
| アナリストカバレッジ | Low |
| 最終更新日 | 09 May 2026 |
今後の成長に関する最新情報
Recent updates
ナラティブの更新 • May 11
LXRX: Phase 3 Pain Readiness And Partnership Prospects Will Drive Repricing
Analysts have lifted their fair value estimate for Lexicon Pharmaceuticals from $3.36 to $3.72, pointing to higher price targets from multiple firms and increased confidence in the pilavapadin program following recent clinical and regulatory progress. Analyst Commentary Recent Street research on Lexicon Pharmaceuticals highlights a mix of optimism around pilavapadin and caution around execution and deal timing, which feeds directly into fair value assumptions and risk assessments.ナラティブの更新 • Apr 25
LXRX: Phase 3 Pain Program And Partnership Expectations Will Drive Repricing
Narrative Update Analysts have raised their price targets on Lexicon Pharmaceuticals to a range of about $2.30 to $6.00. They cite increased confidence in the pilavapadin program, particularly a higher assessed probability of success and expectations for a potential partnership on the Phase 3 ready asset.ナラティブの更新 • Apr 06
LXRX: Phase 3 Pain Program Progress And Partnership Expectations May Support Upside
Analysts have raised their average price targets for Lexicon Pharmaceuticals, with moves such as Citi's shift from $2.10 to $2.30 and H.C. Wainwright's adjustment from $4 to $6, citing a higher assumed probability of success for pilavapadin and progress on clinical and regulatory work that they see as reducing program risk. Analyst Commentary Recent Street research on Lexicon Pharmaceuticals points to a generally constructive tone, with higher price targets linked to views on pilavapadin and the perceived risk profile of the pipeline.ナラティブの更新 • Mar 21
LXRX: Phase 3 Pain Program And Key Partnership Potential May Drive Upside
Analysts have nudged the fair value estimate for Lexicon Pharmaceuticals higher to $3.36 from $3.32, reflecting updated assumptions around revenue growth, profit margins and future P/E multiples following recent price target increases to $2.30 at one firm and $6 at another. Analyst Commentary Recent research updates offer a mixed picture on Lexicon Pharmaceuticals, with higher price targets tied closely to progress on its pipeline, particularly pilavapadin, and expectations around future execution.ナラティブの更新 • Mar 07
LXRX: Phase 3 Pain Program And Partnership Prospects Will Support Future Upside
Analysts have raised their price targets on Lexicon Pharmaceuticals, with one moving from $4 to $6, citing a higher assumed probability of success for pilavapadin and the potential for an important partnership on this Phase 3 ready program. Analyst Commentary Bullish Takeaways Bullish analysts see the higher assumed probability of success for pilavapadin, at 30% versus the prior 15%, as a key input to higher valuation for Lexicon, particularly as the program is described as Phase 3 ready.ナラティブの更新 • Feb 21
LXRX: Phase 3 Pain Program Progress Will Support Stronger Future Earnings Power
Analysts have raised their price target on Lexicon Pharmaceuticals by $0.20, citing updated assumptions around discount rates, profit margin expectations, and future P/E levels that refine their view of the stock's risk and earnings power. Analyst Commentary Analysts raising the price target by $0.20 are fine tuning their models rather than making a sweeping call, and their commentary gives you a sense of what they think could go right or wrong from here.ナラティブの更新 • Jan 27
LXRX: Phase 3 Pain Program Progress Will Support Higher Future Earnings Power
Analysts have nudged their price target for Lexicon Pharmaceuticals higher, with fair value moving from US$2.75 to US$2.92 as they factor in updated views on discount rates, revenue growth, profit margins and future P/E multiples. Analyst Commentary Analysts updating their models around Lexicon Pharmaceuticals are using the new fair value estimate of US$2.92 as a reference point, linking it to assumptions on discount rates, revenue trajectories, margins and future P/E levels.Seeking Alpha • Jan 22
Lexicon Pharmaceuticals: 'Hold' As FDA Feedback Allows Pilavapadin For DPNP To Go Forward
Summary Lexicon Pharmaceuticals is downgraded to a 'Hold' rating due to repeated FDA rejections of ZYNQUISTA for T1D and uncertain near-term catalysts. LXRX plans to resubmit ZYNQUISTA’s NDA in 2026, contingent on positive safety data from the ongoing STENO1 study. Positive FDA feedback enables pilavapadin to advance into two short, registrational Phase 3 studies for diabetic peripheral neuropathic pain (DPNP). Strong cash position ($125.2M) and potential milestone payments provide runway into 2027, but execution and regulatory risks remain material. Read the full article on Seeking Alpha分析記事 • Jan 22
Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Shares Climb 28% But Its Business Is Yet to Catch Up
Lexicon Pharmaceuticals, Inc. ( NASDAQ:LXRX ) shares have had a really impressive month, gaining 28% after a shaky...分析記事 • Dec 18
Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Oct 02
Revenues Not Telling The Story For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After Shares Rise 28%
Despite an already strong run, Lexicon Pharmaceuticals, Inc. ( NASDAQ:LXRX ) shares have been powering on, with a gain...ナラティブの更新 • Aug 22
Pilavapadin Trials And LX9851 Development Will Expand Treatment Options
Lexicon Pharmaceuticals' price target was revised down to $2.75 as analysts weigh mixed signals: strong Q2 results and management confidence against heightened reliance on positive upcoming PROGRESS trial data as a near-term share catalyst. Analyst Commentary Upward price target revision follows recent Q2 results exceeding expectations.ナラティブの更新 • Aug 07
Pilavapadin Trials And LX9851 Development Will Expand Treatment Options
Despite a sharp downgrade in revenue growth forecasts, Lexicon Pharmaceuticals’ consensus analyst price target has increased notably, supported by a lower future P/E ratio and now stands at $3.05. What's in the News Post-hoc analysis of clinical data showed sotagliflozin reduced hypoglycemia events without increased risk across kidney function subgroups in type 1 diabetes patients using optimized insulin therapy.分析記事 • Jul 28
There's Reason For Concern Over Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Massive 34% Price Jump
Despite an already strong run, Lexicon Pharmaceuticals, Inc. ( NASDAQ:LXRX ) shares have been powering on, with a gain...分析記事 • Jun 13
Revenues Not Telling The Story For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After Shares Rise 31%
Lexicon Pharmaceuticals, Inc. ( NASDAQ:LXRX ) shares have continued their recent momentum with a 31% gain in the last...分析記事 • May 19
Analysts Just Made A Noticeable Upgrade To Their Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Forecasts
Shareholders in Lexicon Pharmaceuticals, Inc. ( NASDAQ:LXRX ) may be thrilled to learn that the analysts have just...分析記事 • May 17
Earnings Update: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Just Reported And Analysts Are Boosting Their Estimates
Lexicon Pharmaceuticals, Inc. ( NASDAQ:LXRX ) investors will be delighted, with the company turning in some strong...
新しいナラティブ • Apr 01
Pilavapadin Trials And LX9851 Development Will Expand Treatment Options
Advancing novel medicines like pilavapadin and LX9851 could significantly impact revenue growth and open high-demand markets.Seeking Alpha • Mar 28
Lexicon's Drug Discovery Engine Validated By Novo's $1 Billion Obesity Drug Deal (Upgrade)
Summary Lexicon's stock rose 60% after securing a potential $1 billion deal with Novo Nordisk for preclinical obesity drug LX9851. The company abandoned its underperforming heart failure drug and shifted focus to becoming a clinical development-focused company. Lexicon's Phase 2b neuropathy trial technically failed but the company plans to advance to Phase 3 trials. With $238 million in cash, Lexicon has financial runway into early 2027 despite monthly burn of $7 million. I upgraded my rating from "Sell" to "Hold" but remain cautious until Lexicon establishes signs of sustainable revenue generation in the future. Read the full article on Seeking Alpha分析記事 • Mar 26
Investors Don't See Light At End Of Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Tunnel And Push Stock Down 50%
The Lexicon Pharmaceuticals, Inc. ( NASDAQ:LXRX ) share price has fared very poorly over the last month, falling by a...Seeking Alpha • Oct 16
Lexicon Faces Uphill Battle As Inpefa Launch Disappoints, Eyes Type 1 Diabetes
Summary Lexicon's Inpefa faces fierce competition from established SGLT2 inhibitors, like Farxiga and Jardiance, making market penetration difficult. Inpefa’s early commercial results are underwhelming, with Q2 revenue of only $1.6 million and rising SG&A costs. Lexicon has pivoted from heart failure to type 1 diabetes, where sotagliflozin could be the first SGLT2 approved for T1D in the U.S. The company’s pipeline includes LX9211 for diabetic peripheral neuropathic pain, though Phase 2 results indicate mixed efficacy and safety concerns. Given strong competition, limited market penetration, and pipeline risks, Lexicon presents a high-risk, low-reward investment opportunity. Read the full article on Seeking Alpha分析記事 • Aug 08
Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Seeking Alpha • Aug 03
Lexicon Pharmaceuticals Needs To See Real Revenue Acceleration And Clinical/Regulatory Success
Summary Lexicon Pharmaceuticals' launch of Inpefa continues to progress very slowly; prescriptions grew nearly 50% QoQ, but revenue is still below $2M and missing sell-side expectations. New leadership and cash reserves provide opportunities for Lexicon to improve commercial execution and drive revenue growth, and improved patient access and payer coverage are 2H'24 priorities. The company has resubmitted its application for Zynquista in Type 1 diabetes, a commercially significant opportunity, but one where regulatory and execution risk are still very present. Lexicon's pipeline is getting more interesting, with LX9211 in diabetic neuropathy and a new candidate for obesity and/or metabolic disease in preclinical testing, but effectively commercializing Inpefa remains critical. Lexicon shares appear undervalued on the basis of Inpefa's commercial opportunity and the risk-adjusted opportunities in Type 1 diabetes, diabetic neuropathy, and hypertrophic cardiomyopathy, but execution risk is very high. Read the full article on Seeking AlphaSeeking Alpha • May 28
Lexicon Pharmaceuticals: Blue Sky Aplenty, Revenue Not So Much
Summary Lexicon Pharmaceuticals has a strong cash position and multiple late-stage assets. However, the company is facing low revenues and high expenses. Overall, Lexicon Pharmaceuticals' financial situation presents a mixed outlook for the company. Read the full article on Seeking Alpha業績と収益の成長予測
| 日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
|---|---|---|---|---|---|
| 12/31/2028 | 76 | -58 | N/A | N/A | 5 |
| 12/31/2027 | 20 | -88 | N/A | N/A | 5 |
| 12/31/2026 | 38 | -67 | N/A | N/A | 5 |
| 3/31/2026 | 70 | -26 | N/A | N/A | N/A |
| 12/31/2025 | 50 | -50 | -68 | -68 | N/A |
| 9/30/2025 | 71 | -69 | -73 | -72 | N/A |
| 6/30/2025 | 58 | -121 | -103 | -102 | N/A |
| 3/31/2025 | 31 | -177 | -168 | -167 | N/A |
| 12/31/2024 | 31 | -200 | -180 | -179 | N/A |
| 9/30/2024 | 5 | -216 | -208 | -208 | N/A |
| 6/30/2024 | 4 | -202 | -196 | -196 | N/A |
| 3/31/2024 | 2 | -194 | -186 | -185 | N/A |
| 12/31/2023 | 1 | -177 | -162 | -162 | N/A |
| 9/30/2023 | 1 | -158 | -135 | -133 | N/A |
| 6/30/2023 | 0 | -131 | -112 | -111 | N/A |
| 3/31/2023 | 0 | -110 | -99 | -97 | N/A |
| 12/31/2022 | 0 | -102 | -90 | -89 | N/A |
| 9/30/2022 | 0 | -97 | -90 | -90 | N/A |
| 6/30/2022 | 0 | -97 | -88 | -88 | N/A |
| 3/31/2022 | 0 | -90 | -87 | -85 | N/A |
| 12/31/2021 | 0 | -88 | -88 | -87 | N/A |
| 9/30/2021 | 0 | -68 | -100 | -98 | N/A |
| 6/30/2021 | 7 | 38 | 38 | -122 | N/A |
| 3/31/2021 | 16 | -13 | 14 | -146 | N/A |
| 12/31/2020 | 24 | -59 | 17 | -143 | N/A |
| 9/30/2020 | 33 | -104 | 27 | -133 | N/A |
| 6/30/2020 | 320 | 39 | 98 | 98 | N/A |
| 3/31/2020 | 321 | 85 | 117 | 117 | N/A |
| 12/31/2019 | 322 | 130 | N/A | 114 | N/A |
| 9/30/2019 | 330 | 164 | N/A | 111 | N/A |
| 6/30/2019 | 43 | -89 | N/A | -102 | N/A |
| 3/31/2019 | 47 | -101 | N/A | -127 | N/A |
| 12/31/2018 | 63 | -121 | N/A | -149 | N/A |
| 9/30/2018 | 81 | -126 | N/A | -155 | N/A |
| 6/30/2018 | 101 | -129 | N/A | -167 | N/A |
| 3/31/2018 | 99 | -130 | N/A | -147 | N/A |
| 12/31/2017 | 92 | -123 | N/A | -185 | N/A |
| 9/30/2017 | 80 | -133 | N/A | -200 | N/A |
| 6/30/2017 | 81 | -138 | N/A | -202 | N/A |
| 3/31/2017 | 89 | -141 | N/A | -217 | N/A |
| 12/31/2016 | 79 | -131 | N/A | -176 | N/A |
| 9/30/2016 | 188 | -22 | N/A | 139 | N/A |
| 6/30/2016 | 160 | -22 | N/A | 149 | N/A |
| 3/31/2016 | 141 | -11 | N/A | 165 | N/A |
| 12/31/2015 | 130 | -5 | N/A | 185 | N/A |
| 9/30/2015 | 24 | -94 | N/A | -86 | N/A |
| 6/30/2015 | 24 | -100 | N/A | -81 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: LXRX今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: LXRX今後 3 年間、利益が出ない状態が続くと予測されています。
高成長収益: LXRX今後 3 年間、利益が出ない状態が続くと予測されています。
収益対市場: LXRXの収益 ( 18% ) US市場 ( 11.7% ) よりも速いペースで成長すると予測されています。
高い収益成長: LXRXの収益 ( 18% ) 20%よりも低い成長が予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: LXRX 3 年以内に赤字になると予測されています。
成長企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/21 14:23 |
| 終値 | 2026/05/21 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Lexicon Pharmaceuticals, Inc. 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。12
| アナリスト | 機関 |
|---|---|
| Yigal Nochomovitz | Citigroup Inc |
| Joseph Pantginis | H.C. Wainwright & Co. |
| Andrew Tsai | Jefferies LLC |